

REMARKS

Claims 1-29 are pending. Applicants have canceled claims 1-12 and 21-29 without prejudice or disclaimer. No new matter is added by way of the foregoing amendments. Upon entry of the present Amendment, claims 13-20 are pending.

In the Office Action, the Examiner required restriction of the pending claims to one of the following inventions under 35 U.S.C. §121:

- I. Claims 1-12, 26, and 27, allegedly drawn to a method of modulating angiogenesis comprising administering to a cell or a mammal an effective amount of STC or variant thereof.
- II. Claims 13-20, allegedly drawn to a method of selectively inhibiting an angiogenic process promoted by a first angiogenic factor but not the angiogenesis process promoted by a second angiogenic factor, comprising administering to a cell exposed to both factors an effective amount of STC-1 or a variant thereof, wherein the STC-1 or a variant thereof inhibits at least one step of the angiogenic process promoted by the first angiogenic factor but not the second angiogenic factor.
- III. Claims 21-25, allegedly drawn to a polypeptide comprising an amino acid sequence of at least 80% identity to the sequence of human STC-1.
- IV. Claims 28 and 29, allegedly drawn to a method of promoting vascularization in a mammal, comprising administering to the mammal an effective amount of an antagonist of STC-1 or a variant thereof.


Applicants elect Group II, claims 13-20, without traverse. Applicants note that claims 1-12 and 21-29 are canceled by way of the above amendments.

Applicants respectfully request entry of these amendments and prosecution on the merits. Please grant any extensions of time and charge any required additional fees to Deposit Account No. 07-0630. The Examiner is invited to contact the undersigned at (650) 225-5530 if any issues may be resolved in that manner.

Respectfully submitted,
GENENTECH, INC.

Date: January 18, 2007

By:



Jennifer L. Elliott, Ph.D.

Reg. No. 50,584

Telephone: (650) 225-2907